Journal
DALTON TRANSACTIONS
Volume 49, Issue 45, Pages 15988-16003Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0dt01365j
Keywords
-
Categories
Funding
- CNPq [303355/2018-2, 308383/2018-4, 403866/2016-2]
- FUNCAP [PRONEX PR2 0101-00030.01.00/15, 3265612/2015]
- Capes/Cofecub [88887.130198/2017-01]
- National Institute of Science and Technology on Tuberculosis (Decit/SCTIE/MS-MCT-CNPq FNDTC-CAPES-FAPERGS) [421703/2017-2]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]
Ask authors/readers for more resources
Medicinal inorganic chemists have provided many strategies to tackle a myriad of diseases, pushing forward the frontiers of pharmacology. As an example, the fight against tuberculosis (TB), an infectious bacterial disease, has led to the development of metal-based compounds as potential drugs. This disease remains a current health issue causing over 1.4 million of deaths per year. The emergence of multi- (MDR) and extensively-drug resistant (XDR) Mycobacterium tuberculosis (Mtb) strains along with a long dormancy process, place major challenges in developing new therapeutic compounds. Isoniazid is a front-line prodrug used against TB with appealing features for coordination chemists, which have been explored in a series of cases reported here. An isoniazid iron-based compound, called IQG-607, has caught our attention, whose in vitro and in vivo studies are advanced and thoroughly discussed, along with other metal complexes. Isoniazid is inactive against dormant Mtb, a hard to eliminate state of this bacillus, found in one-fourth of the world's population and directly implicated in the lengthy treatment of TB (ca. 6 months). Thus, our understanding of this phenomenon may lead to a rational design of new drugs. Along these lines, we describe how metals as targets can cross paths with metals used as selective therapeutics, where we mainly review heme-based sensors, DevS and DosT, as a key system in the Mtb dormancy process and a current drug target. Overall, we report new opportunities for bioinorganic chemists to tackle this longstanding and current threat.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available